A detailed history of Virtus ETF Advisers LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 3,462 shares of IMVT stock, worth $95,239. This represents 0.05% of its overall portfolio holdings.

Number of Shares
3,462
Previous 3,403 1.73%
Holding current value
$95,239
Previous $89,000 6.74%
% of portfolio
0.05%
Previous 0.05%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$27.51 - $27.51 $1,623 - $1,623
59 Added 1.73%
3,462 $95,000
Q2 2024

Aug 14, 2024

BUY
$25.1 - $31.61 $34,437 - $43,368
1,372 Added 67.55%
3,403 $89,000
Q1 2024

May 15, 2024

SELL
$30.27 - $43.79 $4,328 - $6,261
-143 Reduced 6.58%
2,031 $65,000
Q4 2023

Feb 15, 2024

SELL
$31.31 - $44.19 $77,429 - $109,281
-2,473 Reduced 53.22%
2,174 $91,000
Q3 2023

Nov 07, 2023

SELL
$18.55 - $39.96 $8,533 - $18,381
-460 Reduced 9.01%
4,647 $178,000
Q2 2023

Aug 14, 2023

SELL
$14.2 - $23.75 $22,634 - $37,857
-1,594 Reduced 23.79%
5,107 $96,000
Q1 2023

May 15, 2023

SELL
$15.27 - $19.72 $39,320 - $50,779
-2,575 Reduced 27.76%
6,701 $103,000
Q4 2022

Feb 14, 2023

SELL
$6.59 - $17.75 $138,989 - $374,365
-21,091 Reduced 69.45%
9,276 $164,000
Q3 2022

Nov 14, 2022

BUY
$3.93 - $6.37 $868 - $1,407
221 Added 0.73%
30,367 $169,000
Q2 2022

Aug 12, 2022

BUY
$3.38 - $5.65 $30,365 - $50,759
8,984 Added 42.45%
30,146 $118,000
Q1 2022

May 16, 2022

SELL
$5.06 - $8.77 $6,441 - $11,164
-1,273 Reduced 5.67%
21,162 $117,000
Q4 2021

Feb 14, 2022

BUY
$7.33 - $9.32 $19,358 - $24,614
2,641 Added 13.34%
22,435 $191,000
Q3 2021

Nov 15, 2021

SELL
$7.01 - $11.37 $7,241 - $11,745
-1,033 Reduced 4.96%
19,794 $172,000
Q2 2021

Aug 10, 2021

BUY
$9.4 - $16.85 $138,029 - $247,425
14,684 Added 239.04%
20,827 $220,000
Q1 2021

May 17, 2021

BUY
$13.08 - $49.6 $1,504 - $5,704
115 Added 1.91%
6,143 $99,000
Q4 2020

Feb 12, 2021

BUY
$36.36 - $52.71 $219,178 - $317,735
6,028 New
6,028 $278,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.